SG Americas Securities
FPRX

SG Americas Securities’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

SG Americas Securities’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,648
Closed -$1.53M – 3435
2021
Q1 		$1.53M Buy
40,648
+31,279
+334% +$780K 0.01% 1232
2020
Q4 		$159K Buy
+9,369
New +$117K ﹤0.01% 2766
2020
Q3 		– Sell
-106,939
Closed -$652K – 3778
2020
Q2 		$652K Buy
106,939
+46,336
+76% +$191K 0.01% 1836
2020
Q1 		$138K Buy
+60,603
New +$257K ﹤0.01% 2773
2017
Q1 		– Sell
-3,215
Closed -$161K – 3661
2016
Q4 		$161K Buy
+3,215
New +$169K ﹤0.01% 2526
2016
Q2 		– Sell
-6,812
Closed -$277K – 3132
2016
Q1 		$277K Buy
+6,812
New +$234K ﹤0.01% 2029

SG Americas Securities's FPRX Position: Q2 2021 in Review

SG Americas Securities sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 40,648 shares — an estimated $1.53M sold.

SG Americas Securities first reported a position in FPRX in Q1 2016 and held it in 6 quarters. The position peaked at $1.53M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • SG Americas Securities reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • SG Americas Securities sold 40,648 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.53M.
  • SG Americas Securities first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
  • SG Americas Securities's Five Prime Therapeutics, Inc. position peaked at $1.53M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on SG Americas Securities's 13F filing for Q2 2021, filed 12 Aug 2021.